Heart and lung health

Pulmonary hypertension: types, symptoms, causes and treatment

Pulmonary hypertension is high pressure in the arteries of the lungs, which strains the right side of the heart. Learn about the five types, symptoms, diagnosis and treatment, and what recent trials show.

Pulmonary hypertension at a glance

Evidence-based
How common it is and how it is defined
About 1%
Of people worldwide
Above 20 mmHg
Mean pulmonary artery pressure at rest
5 groups
Classified by cause

Act quickly

Signs that need urgent care

Fainting or near fainting
Chest pain or pressure
Severe shortness of breath, especially at rest
Bluish lips or skin
Sudden worsening of breathlessness in someone with known pulmonary hypertension

Call emergency services for any of these signs. Contact your care team promptly for new swelling in the legs or abdomen, or breathlessness that is getting worse.

See all symptoms →

The basics

What is pulmonary hypertension?

Pulmonary hypertension (PH) is persistently high pressure in the arteries that carry blood from the heart to the lungs. This forces the right side of the heart to work harder.

Diagnosis depends on pressure measured during right heart catheterization. The 6th World Symposium on Pulmonary Hypertension (Simonneau et al., European Respiratory Journal, 2019) proposed that a mean pulmonary arterial pressure above 20 mmHg at rest is abnormal, replacing the older cut-off of 25 mmHg.

The same task force added a pulmonary vascular resistance of at least 3 Wood units to the definition of pre-capillary forms, in which the problem lies in the lung vessels themselves. The 2022 European guidelines (ESC/ERS) kept the pressure cut-off above 20 mmHg and use a resistance above 2 Wood units for pre-capillary disease.

Hoeper and colleagues estimated in The Lancet Respiratory Medicine (2016) that about 1% of the global population has pulmonary hypertension, rising to as much as 10% among people older than 65. Left heart disease and lung disease have become the most frequent causes in almost all parts of the world, and about 80% of patients live in developing countries.

Pulmonary arterial hypertension (PAH) is the best-known form, but it is only one of five groups. Each group has different causes, treatments and outcomes.

Classification by cause

What are the five types of pulmonary hypertension?

The five groups of pulmonary hypertension are pulmonary arterial hypertension, PH due to left heart disease, PH due to lung disease or low oxygen, chronic thromboembolic PH, and PH with unclear or multiple causes.

The World Health Organization classifies these groups by cause, as described by Hoeper and colleagues (Deutsches Ärzteblatt International, 2017). The underlying cause determines what happens in the lung vessels and helps doctors choose treatment.

GroupNameWhat happensTypical causes
1Pulmonary arterial hypertension (PAH)The small lung arteries narrow and stiffen, so the heart must push harder to move blood through themUnknown cause (idiopathic), inherited forms, appetite-suppressant drugs, HIV, connective tissue disease
2Left heart diseasePressure from a failing or leaking left heart backs up into the lungsHeart failure, mitral or aortic valve disease
3Lung disease or low oxygenDamaged lung tissue and low oxygen make lung vessels constrictCOPD, interstitial lung disease
4Chronic thromboembolic PH (CTEPH)Old blood clots leave the lung arteries blocked or narrowedPrevious pulmonary embolism
5Unclear or multiple causesSeveral mechanisms combine, or the mechanism is not understoodBlood disorders, sarcoidosis, metabolic disorders

Breathlessness and reduced exercise capacity occur in every group, so tests are needed to tell the groups apart.

Classification by severity

What are the functional classes of pulmonary hypertension?

Functional classes describe how much pulmonary hypertension limits everyday activity, from class I with no limitation to class IV with symptoms at rest.

You can move between functional classes as the disease changes or treatment takes effect. The distinction depends on whether symptoms occur during ordinary activity, with less exertion or at rest.

ClassPhysical activityWhat it feels like
INo limitationOrdinary activity does not cause breathlessness, fatigue, chest pain or near fainting
IISlight limitationComfortable at rest, but ordinary activity such as light housework or a brisk walk causes symptoms
IIIMarked limitationComfortable at rest, but less than ordinary activity, such as a short walk, causes symptoms
IVUnable to do any activity without symptomsSymptoms are present at rest, and signs of right heart failure may appear

Many trials enroll people in class II or III, including the AMBITION and STELLAR trials discussed in the treatment section.

Symptoms

What are the symptoms of pulmonary hypertension?

The main symptoms of pulmonary hypertension are shortness of breath, tiredness, chest pain or pressure, dizziness or fainting, and swelling in the ankles, legs or abdomen.

Breathlessness usually appears first during exertion and may later occur at rest. The other symptoms can appear as the right side of the heart struggles to keep up.

Shortness of breath. Often first noticed on stairs or during a walk, and the symptom that most often brings people to a doctor.
Fatigue. Unusual tiredness or weakness that limits daily activities.
Chest pain or pressure. Typically during activity, when the heart works harder to push blood through narrowed arteries.
Dizziness or fainting. Reduced blood flow can cause light-headedness, especially after exertion.
Swelling. Fluid collects in the ankles and legs and later in the abdomen, a sign that the right heart is under strain.
Palpitations. A fluttering or pounding heartbeat.
Bluish lips or skin. A sign of low oxygen in the blood.

These symptoms overlap with asthma, heart failure and other heart and lung conditions, so pulmonary hypertension is easy to miss in the early stages.

When should you seek urgent help?

Seek emergency care for fainting, chest pain or pressure, severe breathlessness at rest or blue lips.

Contact your care team promptly about breathlessness or fatigue that worsens faster than usual, sudden swelling or weight gain, a fever or cough that could signal an infection, or medication side effects. Ask the team before starting any new medicine or supplement, because some interact with pulmonary hypertension treatment.

Causes and risk

What causes pulmonary hypertension and who is at risk?

The causes of pulmonary hypertension depend on the group, ranging from changes in the small lung arteries (group 1) and left heart disease (group 2) to chronic lung disease (group 3), chronic blood clots (group 4) and mixed mechanisms (group 5).

In PAH, the cause is often not found. Appetite-suppressant drugs are the clearest drug risk: an international case-control study of 95 patients and 355 controls (Abenhaim et al., New England Journal of Medicine, 1996) linked the use of fenfluramine-type appetite suppressants to primary pulmonary hypertension.

The odds ratio was 6.3 for any use and 23.1 when the drugs were taken for more than three months. The study also confirmed a family history of pulmonary hypertension, HIV infection, cirrhosis and the use of cocaine or intravenous drugs as risk factors.

PAH affects women far more often than men. In the US REVEAL registry (Badesch et al., Chest, 2010), 2,007 of 2,525 adults with PAH, or 79.5%, were women, and the mean age was 53 years, older than in earlier descriptions.

Chronic thromboembolic disease (group 4) can follow a pulmonary embolism, although it is uncommon. A meta-analysis of 16 studies and 4,047 patients (Ende-Verhaar et al., European Respiratory Journal, 2017) found an incidence of 0.56% among all patients with an embolism and about 3% among survivors.

Chronic thromboembolic pulmonary hypertension after pulmonary embolism

Pooled incidence in each group of patients followed for the condition.

Patient groupPooled incidence (%)
All patients with pulmonary embolism0.56
Survivors of pulmonary embolism3.2
Survivors without major comorbidities2.8
Source: Ende-Verhaar et al., European Respiratory Journal, 2017, meta-analysis of 16 studies and 4,047 patients (1,186 all-comers, 999 survivors, 1,775 survivors without major comorbidities). The authors consider 0.56% the best population-level estimate and about 3% more relevant for clinical practice.

A recurrent clot (odds ratio 3.2) and an embolism with no clear trigger (odds ratio 4.1) were linked to a higher risk. Breathlessness that persists after a pulmonary embolism is a reason to see your doctor.

Connective tissue diseases such as scleroderma and lupus, sickle cell disease and long-term residence at high altitude are also linked to pulmonary hypertension. Our guide to hypertension explains the separate, far more common condition of high pressure in the body's arteries.

Diagnosis

How is pulmonary hypertension diagnosed?

Doctors confirm pulmonary hypertension with right heart catheterization, which measures pressure inside the pulmonary artery. Symptoms, a physical examination and an echocardiogram help doctors recognize suspected PH.

The assessment also looks for the cause of PH and how severely it affects the heart, lungs and exercise capacity.

Echocardiogram. A heart ultrasound that estimates pressure in the lung arteries and shows how the right ventricle is coping.
Electrocardiogram and chest X-ray. Tests that look for heart rhythm changes, an enlarged pulmonary artery and lung disease.
Lung function tests. Tests for the airway and lung conditions associated with group 3 PH.
Ventilation-perfusion scan. The key test for chronic clots, sometimes followed by a CT scan or angiography.
Blood tests. Tests for conditions that can cause PH, such as HIV, liver disease or autoimmune disease.
Six-minute walk test. A measure of exercise capacity, repeated to track the response to treatment.
Right heart catheterization. A thin tube is passed into the pulmonary artery to measure pressure directly and confirm the diagnosis.

The catheter also records the pulmonary arterial wedge pressure, which helps separate PH caused by left heart disease from PH that starts in the lung vessels (Vachiéry et al., European Respiratory Journal, 2019).

After diagnosis, doctors assess risk to guide treatment, taking the PH group and any other illnesses into account, as Hoeper and colleagues describe. Severe forms are best managed in cooperation with a specialized center.

Treatment

How is pulmonary hypertension treated?

Treatment for pulmonary hypertension depends on its cause: targeted drugs for PAH, treatment of the underlying condition for PH due to left heart or lung disease, and surgery for chronic thromboembolic disease when possible.

In their review of PAH treatment, Hoeper and colleagues described ten drugs from five substance classes, often given in combination. The classes include endothelin receptor antagonists, PDE-5 inhibitors, guanylate cyclase stimulators and drugs acting on the prostacyclin pathway.

The AMBITION trial tested starting two drugs together (Galiè et al., New England Journal of Medicine, 2015). It randomized 500 people with untreated PAH in functional class II or III to ambrisentan plus tadalafil, or to either drug alone.

Clinical failure, a composite of death, hospitalization, disease progression or an unsatisfactory response, occurred in 18% of the combination group compared with 34% on ambrisentan and 28% on tadalafil. The hazard ratio compared with the pooled single-drug groups was 0.50 (95% CI 0.35 to 0.72).

Initial combination therapy in pulmonary arterial hypertension (AMBITION)

Share of participants with a clinical failure event: death, hospitalization, progression or unsatisfactory response.

GroupClinical failure (% of participants)
Ambrisentan + tadalafil18
Ambrisentan alone34
Tadalafil alone28
Source: Galiè et al., New England Journal of Medicine, 2015. 500 participants with untreated PAH in WHO functional class II or III (253 combination, 126 ambrisentan, 121 tadalafil). Events occurred in 31% of the pooled monotherapy groups; hazard ratio for combination versus pooled monotherapy 0.50 (95% CI 0.35 to 0.72).

A newer option is sotatercept, which targets a different pathway. In the STELLAR trial (Hoeper et al., New England Journal of Medicine, 2023), 323 adults already on stable PAH therapy received sotatercept or placebo every three weeks.

At week 24, the median change in six-minute walk distance was 34.4 m with sotatercept and 1.0 m with placebo; the estimated between-group difference was 40.8 m (Hodges-Lehmann estimate, 95% CI 27.5 to 54.1).

Calcium channel blockers are an option for a small group of people with PAH, and their use requires specialist testing. In a referral-center series of 557 patients with idiopathic PAH (Sitbon et al., Circulation, 2005), 70 (12.6%) responded to a vasodilator test and received calcium channel blockers, but only 38 (6.8%) continued to do well after a year or more.

PH caused by left heart disease responds poorly to PAH drugs. Vachiéry and colleagues (European Respiratory Journal, 2019) noted that recent trials did not show a benefit from PAH-approved therapies in this group, so care focuses on the heart condition.

For group 3 PH associated with interstitial lung disease, researchers have studied inhaled treprostinil. In the INCREASE trial (Waxman et al., New England Journal of Medicine, 2021), 326 patients received inhaled treprostinil or placebo for 16 weeks, with a 31.12 m greater improvement in six-minute walk distance with treprostinil (95% CI 16.85 to 45.39).

Group 4 can sometimes be cured by surgery to remove old clots from the lung arteries, an operation called pulmonary endarterectomy. In an international registry of 679 newly diagnosed patients (Pepke-Zaba et al., Circulation, 2011), 62.9% were considered operable.

The reported mortality for the operation was 4.7%, and the median time from first symptoms to diagnosis was 14.1 months. People who cannot have surgery are treated with drugs and endovascular procedures.

Supportive care includes oxygen when blood oxygen is low, diuretics for fluid retention and, in selected people, anticoagulants. A lung or heart-lung transplant is considered when other treatment fails.

Outlook

What is the outlook for pulmonary hypertension?

The outlook for pulmonary hypertension depends on its group, how early it is found and how well treatment works. Care is usually long-term.

Can pulmonary hypertension be cured?

Most forms of pulmonary hypertension cannot be cured, although treatment can ease symptoms and slow progression. Chronic thromboembolic disease is the main exception because surgery can cure many cases.

The NHS also describes treatment as a way to reduce symptoms and manage the condition. When another disease causes PH, treating that disease is part of the plan.

Is pulmonary hypertension fatal?

Pulmonary hypertension can be life-threatening because sustained high pressure overloads the right ventricle and can lead to right heart failure.

In the French national registry, 674 adults with PAH were followed for three years (Humbert et al., European Respiratory Journal, 2010). Survival was 87% at one year, 76% at two years and 67% at three years.

Survival in pulmonary arterial hypertension over three years

Share of patients alive after study entry in the French national registry.

Time since study entrySurvival (%)
1 year87
2 years76
3 years67
Source: Humbert et al., European Respiratory Journal, 2010, 674 consecutive adults enrolled in the French PAH registry (121 incident and 553 prevalent cases). Registry data predate newer treatments such as sotatercept.

These figures come from a registry published in 2010, before drugs such as sotatercept were available, so outcomes today may differ.

Daily life

Which lifestyle measures help with pulmonary hypertension?

Supervised exercise training is supported by randomized trials in pulmonary hypertension, and it complements treatment with medicines.

A Cochrane review of 14 randomized trials (Morris et al., 2023) found that participants walked 48.52 m farther in the six-minute walk test after exercise-based rehabilitation than those in control groups (95% CI 33.42 to 63.62; 418 participants in that analysis). The certainty of the evidence was low, and most participants were women with PAH.

An earlier randomized trial of 30 people on stable medication (Mereles et al., Circulation, 2006) added respiratory and physical training to usual care. After 15 weeks, the training group walked 111 m farther than the control group (95% CI 65 to 139 m).

Your PH team should set your exercise plan because the right intensity depends on the type and severity of disease. Stopping smoking is also part of daily care; advice on salt and fluids depends on whether you retain fluid, so follow your team's guidance.

Ask your care team before using any supplement or herbal remedy, since their value in pulmonary hypertension is not established and some interact with PH medicines.

Prevention

Can pulmonary hypertension be prevented?

Pulmonary hypertension cannot always be prevented, because inherited forms and chronic diseases lie outside your control, but several risks can be reduced.

Avoiding appetite-suppressant drugs and cocaine or intravenous drug use removes the clearest drug risks described in the causes section. Treating heart and lung disease and seeing a doctor for persistent breathlessness after a pulmonary embolism help identify group 2, 3 and 4 disease early.

Not smoking protects the lungs and blood vessels. A healthy weight and regular activity support the heart, as explained in our guides to lowering blood pressure and the blood pressure diet.

Monitoring

Can a home blood pressure monitor detect pulmonary hypertension?

A home blood pressure monitor cannot detect pulmonary hypertension, because its cuff measures pressure in the arm arteries, while pulmonary pressure is measured with a catheter in the pulmonary artery.

Normal cuff readings do not rule out PH, and high readings do not mean you have it.

Home monitoring still has a role when you also have high blood pressure, heart failure or another heart condition, since these are common causes of group 2 disease. Choose a validated upper-arm monitor and take readings while seated, using our guides to measuring at home and choosing a monitor.

Quick answers

Common questions about pulmonary hypertension

Is pregnancy safe with pulmonary hypertension?

Pregnancy is considered high risk in pulmonary hypertension, and consensus guidelines recommend against it.

The Pulmonary Vascular Research Institute statement (Hemnes et al., Pulmonary Circulation, 2015) notes that outcomes remain poor despite advanced therapies and offers 38 consensus-based recommendations on avoiding and managing pregnancy. Speak with your PH team about contraception before you try to conceive.

Why is pulmonary hypertension often diagnosed late?

Pulmonary hypertension is often diagnosed late because its early symptoms resemble more common conditions.

In the REVEAL registry (Badesch et al., Chest, 2010), the average time from first symptoms to diagnostic catheterization was 2.8 years. A follow-up analysis (Brown et al., Chest, 2011) found that 21.1% of 2,967 patients had symptoms for more than two years before diagnosis, with the longest delays in those whose symptoms began before age 36 (odds ratio 3.07) and in people with obstructive airways disease or sleep apnea.

Are anxiety and depression common in pulmonary hypertension?

Anxiety and depression are common in pulmonary arterial hypertension, and they are often missed.

A review (Bussotti and Sommaruga, Vascular Health and Risk Management, 2018) reported depression in 7.5% to 53% of patients and anxiety or panic disorders in 19% to 51%. The European guidelines recommend psychological support, although the review found no evidence for any specific psychological intervention in this group; tell your care team how you feel.

What does the six-minute walk test show?

The six-minute walk test measures how far you can walk in six minutes, helping doctors track your exercise capacity and response to treatment.

It is the main outcome in many trials, including STELLAR, where the estimated difference between sotatercept and placebo was 40.8 m. The 2017 Cochrane review on exercise training described 30 m as the minimal important difference.

Michael Rotman
Michael Rotman

Michael Rotman is a structural heart specialist, interventional cardiologist and scientist. He has more than a decade of experience treating heart disease and writing and reviewing health content, and he currently works at St. Michael's Hospital in Toronto.

Email | Instagram | Twitter